The enzyme replacement therapy market in Asia Pacific is expected to grow from US$ 2,415.74 million in 2022 to US$ 3,783.02 million by 2028. It is estimated to grow at a CAGR of 7.8% from 2022 to 2028.
Innovative Developments in Enzyme Replacement Therapy
Enzyme replacement therapy administration typically requires 1–2 hours and is repeated monthly. Infusions are usually administered at infusion centers; however, under certain conditions, they can be administered at home by a nurse. Enzyme testing is usually the initial diagnostic test, but genetic analysis of gene mutations adds precision. For instance, small-molecule therapies, including substrate reduction and chaperone therapies, have also been developed and are approved for a few lysosomal storage diseases (LSDs). Additionally, companies are working to develop new therapies at the genomic level. For instance, SmartPharm is working to replace the administration of recombinant proteins by introducing the gene into the body to make the protein available over a long period. Successful gene-encoded therapeutics are expected to prolong the period between treatments. It could eliminate the infrastructure of infusion now required to deliver these proteins, thus freeing the patients from burdens related to current enzyme replacement therapy administration. Therefore, the trend of combining gene therapy with enzyme replacement therapy is expected to grow during the forecast period.
Market Overview
The enzyme replacement therapy market in Asia Pacific is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. The APAC enzyme replacement therapy market in Japan is growing due to robust research and increasing ERT product approvals. For instance, in March 2022, Sanofi announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) granted marketing authorization for Xenpozyme (olipudase alfa) for the treatment of acid sphingomyelinase deficiency (ASMD). Also, Xenpozyme is the first and only approved therapy in Japan indicated to treat acid sphingomyelinase deficiency. Moreover, Japan's technologically advanced environment helps companies develop new products. For instance, in March 2021, JCR Pharmaceuticals announced the approval of IZCARGO (Pabinafusp Alfa) to treat Hunter syndrome. Thus, technological advancement and rising drug approvals are expected to fuel the enzyme replacement therapy market in Japan during the forecast period.
Asia Pacific Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Enzyme Replacement Therapy Market Segmentation
The Asia Pacific enzyme replacement therapy market is segmented into enzyme type, therapeutic conditions, route of administration, end user, and country.
By therapeutic conditions, the Asia Pacific enzyme replacement therapy market is segmented into Gaucher's disease, Fabry's disease, MPS, Pompe's disease, SCID, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2022.
In terms of route of administration, the Asia Pacific enzyme replacement therapy market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2022.
From end user point of reference, the Asia Pacific enzyme replacement therapy market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2022.
Sanofi; BioMarine Pharmaceutical Inc; Takeda Pharmaceutical Company Limited; AbbVie Inc; Janssen Pharmaceutical (Johnson & Johnson Services, Inc.); Alexion Pharmaceutical, Inc. (AstaZeneca); Amicus Therapeutics; Recordati S.p.A; Recordati S.p.A; CHIESI farmaceutici S.p.A; and Pfizer Inc are the leading companies operating in the enzyme replacement therapy market in Asia Pacific.